New Treatments for MS
Multiple sclerosis (MS) is a chronic, debilitating, inflammatory disorder of the central nervous system (brain, spinal cord, and optic nerves). MS damages the protective insulation (called myelin) that surrounds the nerves and may also damage the nerves. This interferes with the ability of nerve cells to communicate with each other, producing the variety of symptoms that may occur, such as weakness, balance problems, and issues with vision.
At this time, there is no single, definitive laboratory test to diagnose MS and no cure for MS, but affiliated physicians and researchers at MNI are continually searching for new treatments.
Our mission is to help patients gain control of their MS and regain their desired quality of life by applying the most comprehensive diagnostic and treatment methods available.
Join us for a discussion with expert neurologist Jerry Wolinsky, M.D., from noon to 1 p.m. Thursday, March 27th to learn more about the latest MS therapies.
- What is Multiple Sclerosis?
- What are the symptoms?
- What are the current symptomatic and
disease management treatments?
- Why does it takes so long to get
discoveries from the laboratory to the clinic?
- What new innovations
are on the horizon?
About the Host
Jerry S. Wolinsky, M.D.
- Dr. Wolinsky is the Interim Chair and Bartels Family and Opal C. Rankin Professor, Department of Neurology at UTHealth Medical School and director of the Multiple Sclerosis Research Group and the Magnetic Resonance Imaging Analysis Center
- He received his medical degree from The University of Illinois in 1969, and completed his residency in clinical neurology and a fellowship in experimental neuropathology at The University of California San Francisco. After being appointed to a faculty position there, he joined the faculty of The Johns Hopkins University Schools of Medicine, and Hygiene and Public Health in 1978
- Dr. Wolinsky is active in researching treatments for multiple sclerosis. He has served on review and advisory committees of the National Institutes of Health, the National Multiple Sclerosis Society, the Multiple Sclerosis International Federation, the Food and Drug Administration, numerous pharmaceutical houses, and the Sylvia Lawry Centre for Multiple Sclerosis Research